Orphan status for Mesoblast
Wednesday, 17 September, 2008
The US FDA has granted orphan drug designation for the use of adult stem cells developed by Mesoblast [ASX: MSB] in patients undergoing bone marrow transplantation.
Mesoblast's sister company Angioblast Systems has been granted the right to use its allogeneic mesenchymal precursor cells in patients with haematologic malignancies which have proven unresponsive to conventional chemotherapy.
The orphan drug designation is reserved for diseases affecting fewer than 200,000 patients annually.
It allows for an accelerated review process by the FDA, seven year exclusivity in the market and various tax benefits.
TGA approves first treatment for geographic atrophy
Australia has become the first country outside of the United States to approve the use of the...
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
